Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582879 · ClinicalTrials.gov registry record
informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
A clinical trial of Chronic Lymphocytic Leukemia (CLL), sponsored by Pharmacyclics.
- Completed
- Registry status
- 1,504
- Enrollment target
- 20
- Study locations
NCT02582879 is a study of Chronic Lymphocytic Leukemia (CLL) that has completed, run by Pharmacyclics. The registered enrollment target is 1,504 participants, above the 140-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (974% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT02582879, a study of Chronic Lymphocytic Leukemia (CLL), has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- 1,504 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed as a multicenter, prospective, observational registry of CLL/SLL patients who are initiating approved oral kinase inhibitors, BCL-2 inhibitors or other approved anti-CLL therapies/regimens. The study will characterize treatment patterns and their association with patient characteristics, healthcare resource utilization, and clinical outcomes, as well as patient-reported outcome (PRO) measures.
Conditions Studied
Study Locations (20)
California
- John Muir Health - Concord
- North County Oncology Medical Clinic - Oceanside
- Sansum Clinic - Santa Barbara
- St Joseph Heritage Healthcare - Santa Rosa
- Sansum Clinic - Solvang
- Gregory Smith, MD (Private Practice) - St. Helena
- Solano Hematology Oncology - Vallejo
Arizona
- Arizona Oncology Associates, PC - HAL - Glendale
- Arizona Oncology Associates, PC - HAL - Phoenix
- Arizona Oncology Associates, PC - HAL - Phoenix
- Arizona Oncology Associates, PC - HAL-Scottsdale - Tempe
Arkansas
- Mercy Research - Fort Smith
- Genesis Cancer Center - Hot Springs
- Clopton Clinic of Jonesboro, Inc. - Jonesboro
- CARTI - Central Arkansas Radiation Therapy Institute - Little Rock
Colorado
- Rocky Mountain Cancer Centers, LLP- Aurora - Aurora
- Rocky Mountain Cancer Centers, LLP- Boulder - Boulder
- Rocky Mountain Cancer Centers - Colorado Springs
Alabama
- Clearview Cancer Institute - Huntsville
- Northwest Alabama Cancer Center, PC - Muscle Shoals
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,504 participants |
| Start Date | 2015-09 |
| Est. Completion | 2021-07-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02582879
The ClinicalTrials.gov registry entry for NCT02582879 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,504 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 140-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (974% higher). The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 0 interventions.
NCT02582879 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02582879 about?
NCT02582879 is a clinical study titled "informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia". The study is designed as a multicenter, prospective, observational registry of CLL/SLL patients who are initiating approved oral kinase inhibitors, BCL-2 inhibitors or other approved anti-CLL therapies/regimens. The study will characterize treatment patterns and their association with patient charac...
What is the current status of trial NCT02582879?
This trial is currently completed. The enrollment target is 1,504 participants. The study started on 2015-09. Estimated completion is 2021-07-21.
What conditions does trial NCT02582879 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL).
Who is sponsoring clinical trial NCT02582879?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02582879 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.